FUBP3 regulates chronic myeloid leukaemia progression through PRC2 complex regulated PAK1‐ERK signalling

M Sharma, S Anandram, C Ross… - Journal of Cellular and …, 2023 - Wiley Online Library
The development of resistance and heterogeneity in differential response towards tyrosine
kinase inhibitors (TKI) in chronic myeloid leukaemia (CML) treatment has led to the …

[HTML][HTML] The impact of additional cytogenetic abnormalities at diagnosis and during therapy with tyrosine kinase inhibitors in Chronic Myeloid Leukaemia

AM Crisan, D Coriu, C Arion, A Colita… - Journal of medicine …, 2015 - ncbi.nlm.nih.gov
Background: Chronic Myeloid Leukemia's (CML) treatment was optimized since the
development of tyrosine kinase inhibitors (TKI) and an increased overall survival during TKI …

[HTML][HTML] Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy

S Luatti, C Baldazzi, G Marzocchi, G Ameli… - Oncotarget, 2017 - ncbi.nlm.nih.gov
At diagnosis, about 5% of Chronic Myeloid Leukemia (CML) patients lacks Philadelphia
chromosome (Ph), despite the presence of the BCR/ABL rearrangement. Two mechanisms …

Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib

A Quintás‐Cardama, H Kantarjian, J Shan, E Jabbour… - Cancer, 2011 - Wiley Online Library
BACKGROUND: Deletions of derivative chromosome 9 are a poor prognostic factor in
patients with chronic myeloid leukemia (CML) treated with hydroxyurea, interferon, or stem …

Chronic myeloid leukemia: current perspectives

Y Zhang, JD Rowley - Clinics in laboratory medicine, 2011 - labmed.theclinics.com
Chronic myeloid leukemia (CML) is a rare type of leukemia (1–2 per 100,000 people) but is
the most common chronic myeloproliferative neoplasm with the proliferation of multiple …

Predictive and Prognostic implications of variant Philadelphia translocations in CML: Experience from a tertiary oncology center in Southern India

GB Kanakasetty, L Kuntejowdahalli, AH Thanky… - … Myeloma and Leukemia, 2017 - Elsevier
Introduction Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized
by Philadelphia (Ph) chromosome with classical t (9; 22)(q34; q11) seen in up to 90% of …

Molecular characterization and follow‐up of five CML patients with new BCR–ABL 1 fusion transcripts

S Huet, S Dulucq, A Chauveau… - Genes …, 2015 - Wiley Online Library
We report five chronic myeloid leukaemia (CML) patients in whom we identified and
characterized undescribed BCR–ABL1 fusion transcripts. We investigated the precise …

Fluorescence in situ hybridization patterns of BCR/ABL1 fusion in chronic myelogenous leukemia at diagnosis

PP Jain, M Parihar, R Ahmed, A Abraham… - Indian Journal of …, 2012 - journals.lww.com
Background: Chronic myelogenous leukemia (CML) is characterised by the t (9; 22)(q34;
q11. 2) which results in the formation of the BCR/ABL1 fusion gene. Occasionally, the t (9; …

Chronic myeloid leukemia

T Fioretos - … and Molecular Genetic Aberrations of Tumor Cells, 2015 - Wiley Online Library
Chronic myeloid leukemia (CML) is a clonal bone marrow (BM) disease characterized by
neoplastic overproduction of, mainly, granulocytes. The treatment of CML has changed …

Update on current monitoring recommendations in chronic myeloid leukemia: practical points for clinical practice

VG Oehler - Hematology 2013, the American Society of …, 2013 - ashpublications.org
Excellent therapeutic options exist for the treatment of chronic-phase chronic myeloid
leukemia (CML) patients. Therefore, managing CML patients has become a more common …